Form FDA 483 · Issued 2025-10-31
Lonza Guangzhou Pharmaceutical Ltd. — FDA Form 483 Analysis
FEI: 3006532186 · Sector: Pharmaceuticals & Sterile/OTC Drugs (Active Pharmaceutical Ingredient Manufacturer) · Lead Investigator: Jonathan A. Vance
FDA Form 483 issued to Lonza Guangzhou Pharmaceutical Ltd. (FEI 3006532186) on 2025-10-31 following an inspection of its active pharmaceutical ingredient manufacturer operations in China. The report documents 5 inspection observations centered on CAPA, Out-of-Specification (OOS) & Complaint Investigations, Master Manufacturing & Batch Production Records (MMR/BPR).
Get Full Annotated 483 Dossier + CAPA Checklist
Instant PDF + CFR Matrix ($79 vs. Redica's $289)
Need Help Fixing These 5 Citations?
Get matched with a vetted 21 CFR remediation consultant
Observation-by-Observation 21 CFR Breakdown (5)
Observation #1 · 21 CFR 211.180(f)
CAPA, Out-of-Specification (OOS) & Complaint Investigations
FIRST-TIME OBSERVATION
Responsible firm officials notified in writing
Inspector Observation Language: "Procedures are not established which are designed to assure that the responsible officials of the firm, if they are not personally involved in or immediately aware of such actions, are notified in writing of [investigations conducted] [recalls] [reports of inspectional observations issued by FDA] [any regulatory actions brought by FDA relating to good manufacturing practices]. Specifically, observed during inspection of Lonza Guangzhou Pharmaceutical Ltd. on 2025-10-31."
Plain-English Meaning: Failure to thoroughly investigate unexplained batch discrepancies, Out-of-Specification lab results, or consumer complaints/adverse events and document root-cause Corrective and Preventive Actions (CAPA).
Standard CAPA Remediation Path: Deploy a closed-loop CAPA and OOS investigation SOP requiring root-cause determination within 30 business days, impact assessment on distributed lots, and effectiveness checks.
Observation #2 · 21 CFR 211.188(b)(1)
Master Manufacturing & Batch Production Records (MMR/BPR)
FIRST-TIME OBSERVATION
Significant Step Accomplishment Dates
Inspector Observation Language: "The batch production and control records are deficient in that they do not include dates of accomplished significant steps. Specifically, observed during inspection of Lonza Guangzhou Pharmaceutical Ltd. on 2025-10-31."
Plain-English Meaning: Missing Master Manufacturing Records (MMRs) or incomplete Batch Production Records (BPRs) lacking exact component weights, lot numbers, yield reconciliation, or second-person verification.
Standard CAPA Remediation Path: Ensure every product SKU has an approved MMR matching the exact label claim and every batch record captures raw material lot traceability, in-process weight/pH checks, and QA release signatures.
Observation #3 · 21 CFR 211.194(e)
Finished Product Testing, Stability & Expiration Dating
FIRST-TIME OBSERVATION
Stability testing records not included
Inspector Observation Language: "Laboratory records do not include complete records of all stability testing performed. Specifically, observed during inspection of Lonza Guangzhou Pharmaceutical Ltd. on 2025-10-31."
Plain-English Meaning: Releasing finished batches without verifying strength/potency/microbiological specs, or placing an expiration/best-by date on labels without supporting real-time or accelerated stability data.
Standard CAPA Remediation Path: Require finished-batch microbiological (USP <2021>/<2022>), heavy metal, and active-assay release testing plus ICH stability chamber protocols supporting every label shelf-life claim.
Observation #4 · 21 CFR 211.198(b)(1)
CAPA, Out-of-Specification (OOS) & Complaint Investigations
FIRST-TIME OBSERVATION
Complaint Record required information
Inspector Observation Language: "Complaint records are deficient in that they do not include the known [name and strength of the drug product] [lot number] [name of complainant] [nature of complaint] [reply to complainant]. Specifically, observed during inspection of Lonza Guangzhou Pharmaceutical Ltd. on 2025-10-31."
Plain-English Meaning: Failure to thoroughly investigate unexplained batch discrepancies, Out-of-Specification lab results, or consumer complaints/adverse events and document root-cause Corrective and Preventive Actions (CAPA).
Standard CAPA Remediation Path: Deploy a closed-loop CAPA and OOS investigation SOP requiring root-cause determination within 30 business days, impact assessment on distributed lots, and effectiveness checks.
Observation #5 · 21 CFR 211.56(c)
Incoming Ingredient Identity Testing & COA Qualification
REPEAT CITATION AT FACILITY
Written procedures lacking for use of pesticides etc.
Inspector Observation Language: "Written procedures are lacking for the use of [rodenticides] [insecticides] [fungicides] [fumigating agents] [cleaning and sanitizing agents] designed to prevent the contamination of [equipment] [components] [drug product containers] [closures] [packaging, labeling materials] [drug products]. Specifically, observed during inspection of Lonza Guangzhou Pharmaceutical Ltd. on 2025-10-31."
Plain-English Meaning: Failure to perform at least one test to verify the identity of every incoming dietary ingredient or raw component before use, or relying on a supplier's Certificate of Analysis (COA) without first qualifying the supplier.
Standard CAPA Remediation Path: Establish SOP-QA-004 requiring FTIR/HPLC/organoleptic identity testing on 100% of incoming dietary ingredient lots and annual audit + 3-lot confirmatory testing before relying on any vendor COA.